Eligibility criteria
Participants were required to have advanced cancer; be scheduled to receive weekly paclitaxel 80mg/m2 as monotherapy or in combination with other agents; provide written informed consent; age >/= 18, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1, and have life expectancy of 3 months or more. Other key inclusion criteria were: adequate bone marrow reserve (Hb >/= 90g/L, neutrophil count >/= 1.5x109/L, platelet count ≥100 × 109/L), hepatic reserve (total bilirubin of ≤20 μmol/L or, for subjects with liver metastasis, ≤30μmol/L; alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN) or, for subjects with liver metastasis, ≤5 × ULN; alkaline phosphatase (ALP) ≤3 × ULN or, for subjects with liver or bone metastasis, ≤5 × ULN, gamma glutamyl transferase (GGT) <10 × ULN), and adequate renal function (calculated creatinine clearance > 50ml/min by Cockcroft-Gault, or Cr <177 μmol /L), willing to fast 8h prior and 4 hour post dose, and refrain from alcohol and caffeine. Concomitant inducers or inhibitors of P-gp or CYP 3A4 or 2C9 were prohibited within 2 weeks of study medicine.